BiotechTube
Agepha Pharma

Agepha Pharma

Vienna, Europe - Other· Est.
agephapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AGEPHA Pharma is a private, commercial-stage European pharmaceutical company with a diversified portfolio spanning prescription drugs, OTC products, and supplements. Its strategic milestones include the 2023 U.S. FDA approval of LODOCO (colchicine) for cardiovascular disease and the expansion of its ophthalmic portfolio through acquisitions. With products available in 47 countries and a family-owned operational model, the company combines a legacy of trust with targeted innovation in specific therapeutic areas.

CardiovascularOphthalmologyGeneral Wellness

Technology Platform

Commercial and development expertise in reformulating, repurposing, and strategically acquiring established small molecule drugs for new indications and markets.

Funding History

1
UndisclosedUndisclosed

Opportunities

The U.S.
FDA approval of LODOCO provides entry into the massive cardiovascular prevention market.
The company's established commercial footprint in 47 countries offers a ready channel for launching and scaling this and other acquired or licensed products.

Risk Factors

Commercial success depends heavily on the uptake of LODOCO in a competitive market.
The company's reliance on repurposed compounds may expose it to patent challenges and generic competition.
As a private, family-owned firm, access to large-scale capital for R&D or acquisitions may be limited.

Competitive Landscape

In cardiovascular disease, LODOCO competes with statins, PCSK9 inhibitors, and other preventive therapies. In ophthalmology, it faces numerous generic and branded competitors. Its OTC and supplement business operates in highly crowded, brand-sensitive consumer health markets.

More companies in Small Molecule Drugs →More companies in Europe - Other →